Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India Avastin Off-Label Use: Roche Defines Responsibility

This article was originally published in Scrip

Executive Summary

Swiss multinational Roche says that it "respects" the Indian regulator's recommendations to permit off label use of its anticancer, Avastin (bevacizumab), but has made it clear that it can't be held responsible for risks associated with prescriptions for indications other than the one the product is approved for.

Advertisement

Related Content

Indian Avastin Biosimilar Arrives Amid Roche's Charges
Indian Avastin Versions Head For Debut; Watch Off-Label Space

Topics

Advertisement
UsernamePublicRestriction

Register

SC064763

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel